Orum Therapeutics, Inc. Logo

Orum Therapeutics, Inc.

Clinical-stage biotech developing degrader-antibody conjugates to treat cancer.

475830 | KO

Overview

Corporate Details

ISIN(s):
KR7475830006
LEI:
Country:
South Korea
Address:
대전광역시 유성구 문지로 281-25, 대전광역시

Description

Orum Therapeutics is a clinical-stage biotechnology company that develops targeted protein degradation (TPD) therapeutics. The company's proprietary TPD²® platform creates a novel class of antibody-drug conjugates (ADCs), referred to as degrader-antibody conjugates (DACs). This technology combines the cell-targeting precision of antibodies with the catalytic action of protein degraders. The approach is designed to selectively deliver payloads to diseased cells to eliminate intracellular proteins that are difficult to target with conventional drugs. Orum's primary focus is on developing treatments for cancer, aiming to improve efficacy and safety over existing therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 00:00
주식등의대량보유상황보고서(일반)
Korean 352.9 KB
2025-08-29 00:00
주식등의대량보유상황보고서(일반)
Korean 348.3 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 382.4 KB
2025-08-08 00:00
주식등의대량보유상황보고서(일반)
Korean 339.8 KB
2025-08-01 00:00
임시주주총회결과
Korean 10.7 KB
2025-08-01 00:00
주식매수선택권부여에관한신고
Korean 21.5 KB
2025-07-25 00:00
주식등의대량보유상황보고서(일반)
Korean 368.6 KB
2025-07-17 00:00
주주총회소집공고
Korean 77.7 KB
2025-07-10 00:00
[기재정정]주주총회소집결의
Korean 16.8 KB
2025-06-25 00:00
주주총회소집결의
Korean 10.7 KB
2025-06-25 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-06-04 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 372.2 KB
2025-06-04 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 360.6 KB
2025-05-26 00:00
기업설명회(IR)개최
Korean 6.7 KB

Automate Your Workflow. Get a real-time feed of all Orum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NGeneBio Co., Ltd. Logo
Develops NGS-based molecular diagnostic products and software for oncology.
South Korea
354200
Nicox S.A. Logo
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
France
COX
NLS Pharmaceutics Ltd. Logo
Clinical-stage biopharma firm developing therapies for rare and complex CNS disorders.
United States of America
NLSP
NovoCure Ltd Logo
Develops a non-invasive cancer therapy using electric fields to disrupt solid tumors.
United States of America
NVCR
NUFORMIX PLC Logo
Pharmaceutical developer using cocrystal technology to repurpose drugs for fibrosis.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Clinical-stage biopharma developing protein degradation therapies for various diseases.
United States of America
NRIX
OLIPASS CORPORATION Logo
An R&D company developing RNA therapeutics using its proprietary OPNA platform.
South Korea
244460
A technology platform for therapeutic antibody discovery using transgenic animals.
United States of America
OABIW
ONCIMMUNE HOLDINGS PLC Logo
Immunodiagnostics company specializing in antibody and autoantibody biomarker signatures.
United Kingdom
ONC
Oncocross Co.,Ltd. Logo
An AI biotechnology firm that develops drugs by predicting drug-disease interactions.
South Korea
382150

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.